drugset
Drugs / Ladarixin
last change Apr 2026 re-read 2 minutes ago

Ladarixin

also known as LDX

targets CXCL8, CXCR1, CXCR2 via inhibition

Developed for
type 1 diabetes mellitus · respiratory system cancer
Investigated by
Dompé Farmaceutici S.p.A · NYU Langone Health

Trials 8 · a red edge is where a trial was stopped

today NCT05815186 · Ph 2 NCT05815173 · Ph 1 NCT05368402 · Ph 2 NCT05035368 · Ph 2 NCT04628481 · Ph 2 NCT04899271 · Ph 2 NCT04854642 · Ph 1 NCT02814838 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT05815173 Aug 2023 → Aug 2027 expected respiratory system cancer NYU Langone Health Recruiting No outcome recorded
Phase 1 NCT04854642 Oct → Dec 2020 — Dompé Farmaceutici S.p.A Completed No outcome recorded
Phase 26 trials
Phase 2 NCT05815186 Apr 2024 → Apr 2025 respiratory system cancer NYU Langone Health Withdrawn No outcome recorded
Phase 2 NCT05368402 Sep 2022 → Sep 2023 type 1 diabetes mellitus Dompé Farmaceutici S.p.A Terminated No outcome recorded
Phase 2 NCT05035368 Sep 2021 → Jun 2023 type 1 diabetes mellitus Dompé Farmaceutici S.p.A Withdrawn No outcome recorded
Phase 2 NCT04628481 Jan 2021 → Mar 2025 type 1 diabetes mellitus Dompé Farmaceutici S.p.A Terminated No outcome recorded
Phase 2 NCT04899271 Dec 2020 → Apr 2023 type 1 diabetes mellitus Dompé Farmaceutici S.p.A Terminated No outcome recorded
Phase 2 NCT02814838 Aug 2016 → May 2019 type 1 diabetes mellitus Dompé Farmaceutici S.p.A Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Ladarixin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02814838 ↗
7

NCT05035368 ↗

NCT05815186 ↗

NCT04899271 ↗

NCT04854642 ↗

NCT05368402 ↗

NCT05815173 ↗

NCT04628481 ↗
Known as LDX “AIM: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did...” PMID 37409229 ↗ Jun 2023
Action Inhibit “an inhibitor of the CXCR1/2 chemokine receptors” PMID 37409229 ↗ Jun 2023
Route Oral “Ladarixin oral capsule” NCT02814838 ↗
Target CXCR1 “an inhibitor of the CXCR1/2 chemokine receptors” PMID 37409229 ↗ Jun 2023